Clinical Report: ApoA1/HDL in Vascular Endothelial Damage and Sepsis Therapy

Overview

Sepsis induces significant reductions in plasma ApoA1 and HDL levels, correlating with vascular endothelial injury and increased mortality. Exogenous supplementation with reconstituted HDL (rHDL) or ApoA1 mimetics shows promise in ameliorating endothelial dysfunction and improving outcomes in sepsis models.

Background

Sepsis is a life-threatening condition characterized by organ dysfunction due to a dysregulated host response to infection, with high global mortality rates. Vascular endothelial injury is a key pathogenic mechanism driving microcirculatory dysfunction and multiorgan failure in sepsis. HDL and its main protein component ApoA1 are markedly decreased during sepsis, and their depletion is associated with endothelial dysfunction and worse clinical outcomes. Therapeutic strategies targeting restoration of ApoA1/HDL levels may mitigate endothelial damage and improve sepsis prognosis.

Data Highlights

Key Findings

• Sepsis and related infections cause significant reductions in plasma HDL and ApoA1 levels, correlating with endothelial dysfunction and increased vascular permeability.
• ApoA1 levels independently predict mortality and vascular impairment in sepsis and severe infections.
• Endothelial injury mechanisms include glycocalyx degradation, increased adhesion molecule expression, apoptosis, and microthrombus formation.
• Exogenous rHDL supplementation reduces inflammatory cytokines, adhesion molecules, and endothelial apoptosis, promoting vascular repair in animal models.
• ApoA1 mimetic peptides and rHDL show therapeutic potential to restore endothelial function and mitigate sepsis-induced vascular damage.

Clinical Implications

Monitoring ApoA1 and HDL levels in sepsis patients may provide prognostic information regarding endothelial injury and mortality risk. Therapeutic strategies involving rHDL or ApoA1 mimetics could represent novel adjunctive treatments to protect vascular endothelium, reduce inflammation, and improve outcomes in sepsis. Further clinical trials are warranted to validate efficacy and safety of these interventions.

Conclusion

ApoA1/HDL depletion is a critical contributor to vascular endothelial injury in sepsis, and supplementation with rHDL or ApoA1 mimetics holds promise as a therapeutic approach to attenuate endothelial dysfunction and improve sepsis prognosis.

References

1. Singer et al. 2016 -- The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
2. Rudd et al. 2020 -- Global, regional, and national sepsis incidence and mortality
3. Zhou et al. 2019 -- Epidemiology and outcomes of sepsis in China
4. Ince et al. 2016 -- The endothelium in sepsis
5. Kilickap et al. 2017 -- ApoA1 and vascular function in severe infections
6. Tso et al. 2020 -- rHDL enhances endothelial progenitor cell repair in endotoxemia
7. COVID-19 studies 2020-2022 -- HDL and ApoA1 levels correlate with disease severity
8. Flavivirus NS1 studies 2018-2021 -- NS1-induced endothelial dysfunction and ApoA1 role
9. Malaria endothelial injury studies 2015-2019 -- ApoA1 correlation with endothelial markers
10. rHDL supplementation studies 2017-2021 -- Anti-inflammatory and endothelial protective effects